Published Date: 17 Mar 2023
A group of researchers from the annual meeting of the American Academy of Orthopedic Surgeons (AAOS) "analyzed the data and...
Read Full NewsQ&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPF
Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.
In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.
Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.
The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.
1.
For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.
2.
We Don't Always Know What's 'Best' for Our Patients
3.
Year in Review: Multiple Myeloma
4.
UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms
5.
After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.
1.
The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting
2.
Precision Oncology Education for Future Cancer Specialists
3.
Deep Learning Fluorescence Imaging for Oral Cancer Surgery: In Silico Depth Quantification
4.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
5.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
How Hematologists Evaluate Persistent Blood Abnormalities
5.
Advances in Modern Cancer Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation